Sale of 400 shares at $2.01 per share.
Reporting Person Gamelin Erick · Officer Title Chief Development Officer · Transaction Code S
Traded Aug 18, 2026 · Disclosed Aug 20, 2026
Source: SEC Form 4 · 0000905148-26-003838 · filed 2026-08-20 · View filing →
Composed from the Form 4 as filed with the SEC. Share counts, prices and dates are the filing's own; the disclosure lag is counted in business days from the transaction date to the filing date. What is a Form 4?
Cite this card
Desq Long. "Acrivon Therapeutics, Inc. (ACRV)." Disclosed 2026-08-20. https://desqlong.com/cards/0000905148-26-003838-1 (retrieved 2026-09-26).